Practical guides for physicians, NPs, PAs and nurses on IV therapy, peptides, regenerative medicine and the business of practicing beyond insurance.

Two 2026 reviews find no clear evidence PRP rebuilds knee cartilage, with low-certainty symptom gains. What clinicians can honestly claim.

The peptide shift hasn't changed FDA rules for stem cells or exosomes. What's approved, what's not, and the compliance checklist for clinicians.

Compounded GLP-1 sourcing in 2026: black mold at two Chinese API suppliers, an 'FDA-approved pharmacy' warning letter, and the Fifth Circuit ruling.